Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

61

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

enthalten in: Current medical research and opinion | 2023

von Martin, T. | Usmani, S. | Schecter, J. | +13

62

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2023

von Paul, B. | Liedtke, M. | Khouri, J. | +14

63

Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX) : a randomized, open-label, phase III trial

enthalten in: Journal of clinical oncology | January 04, 2023

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +19

64

A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

enthalten in: Leukemia & lymphoma | 2022

von Nath, K. | Shekarkhand, T. | Salcedo, M. | +19

65

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Shah, U. | Maclachlan, K. | Derkach, A. | +35

66

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1) : a phase 1b-2, open-label study

enthalten in: The Lancet. Haematology | 2022

von Martin, T. | Lin, Y. | Agha, M. | +20

CommentIn: Lancet Haematol. 2022 Dec;9(12):e866-e868. - PMID 36215987

67

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

enthalten in: Cancer cell | 2022

von Sklavenitis-Pistofidis, R. | Aranha, M. | Redd, R. | +36

CommentIn: Cancer Cell. 2022 Nov 14;40(11):1270-1272. - PMID 36379204

68

Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

enthalten in: Current medical research and opinion | 2022

von Costa, L. | Hari, P. | Berdeja, J. | +24

69

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

enthalten in: Haematologica | 2022

von Usmani, S. | Nahi, H. | Legiec, W. | +25

70

GPRC5D-Targeted CAR T Cells for Myeloma

enthalten in: The New England journal of medicine | 2022

von Mailankody, S. | Devlin, S. | Landa, J. | +35

CommentIn: Nat Rev Clin Oncol. 2022 Dec;19(12):747. - PMID 36253450